FDA accepts Vertex’s BLA for povetacicept in IgA nephropathy, with a PDUFA date of November 30, 2026. Phase 3 RAINIER data show robust efficacy, positioning the dual BAFF/APRIL blocker as a potential first-in-franchise nephrology therapy.
Written By: Disha Jadhav, BPharm
Reviewed By: Pharmacally Editorial Team
Vertex Pharmaceuticals has reached a key regulatory milestone after the U.S. Food and Drug Administration accepted its Biologics License Application (BLA) for povetacicept in adults with immunoglobulin A nephropathy (IgAN).
The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2026.
If approved, povetacicept would become the first commercialized therapy in Vertex’s nephrology franchise. The investigational therapy previously received FDA Breakthrough Therapy Designation for IgAN, highlighting its potential in a disease where many patients continue to experience progressive kidney damage despite available treatments.
Dual BAFF/APRIL Blockade Addresses IgAN Pathogenesis
Povetacicept is an engineered fusion protein that simultaneously inhibits BAFF (B-cell activating factor) and APRIL (a proliferation-inducing ligand), two cytokines that drive B-cell activation and survival. By blocking both pathways, the therapy reduces production of pathogenic antibodies and immune complexes that contribute to kidney inflammation and fibrosis in IgAN.
IgAN is the most common form of primary glomerulonephritis, affecting an estimated 330,000 people across the United States and Europe and more than 1.5 million worldwide. The disease is characterized by deposition of galactose-deficient IgA1-containing immune complexes in the kidneys, leading to progressive loss of kidney function.
Phase 3 Data Support FDA Filing
The BLA is supported by positive results from the Phase 3 RAINIER trial (NCT06564142), a global randomized, double-blind, placebo-controlled study that enrolled 605 adults, making it the largest IgAN trial conducted to date.
At the pre-specified Week 36 interim analysis, povetacicept met its primary endpoint. Patients achieved a 52.0% reduction in urine protein-to-creatinine ratio (UPCR) from baseline, corresponding to a placebo-adjusted reduction of 49.8% (P<0.0001). Benefits were consistent across predefined patient subgroups.
The study also met key secondary endpoints. Treatment reduced serum galactose-deficient IgA1 levels by 79.3% versus placebo (P<0.0001). Among patients with baseline hematuria, 85.1% achieved hematuria resolution compared with 23.4% in the placebo group, representing a treatment difference of 61.7% (P<0.0001).
Povetacicept was generally well tolerated. Most adverse events were mild to moderate, and investigators reported no treatment-related serious adverse events. Anti-drug antibodies were observed as expected but showed no impact on efficacy or safety.
Safety, Convenience, and Future Outlook
Vertex plans to launch povetacicept as a low-volume subcutaneous autoinjector administered once every four weeks at home. Monthly dosing could reduce treatment burden compared with therapies requiring more frequent administration.
Beyond IgAN, povetacicept is being evaluated in the Phase 2/3 OLYMPUS trial (NCT07204275) in primary membranous nephropathy and the Phase 2 ETNA study (NCT07501702) in generalized myasthenia gravis. The ongoing RAINIER trial will continue through Week 104, with final analysis focused on total estimated glomerular filtration rate (eGFR) slope, a key measure of long-term kidney function preservation.
Reference
About the Writer
Disha Sanjay Jadhav (LinkedIn) is a pharmacy graduate and healthcare writer with a strong interest in clinical documentation and simplifying healthcare information for better reader understanding. She is enthusiastic, adaptable, and eager to take on new challenges while contributing to clear, accurate, and engaging medical and pharmaceutical content.